SynthesisJournal of cardiovascular translational research2022
Venoarterial Extracorporeal Membrane Oxygenation for Acute Massive Pulmonary Embolism: a Meta-Analysis and Call to Action.
Synthesis in Journal of cardiovascular translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- The use of Veno-arterial Extracorporeal Membrane Oxygenation (VA-ECMO) for Acute High Risk Pulmonary Embolism: A Systematic Review.Current cardiology reviews · 2025Pooled it
- Global hotspot and trend of extracorporeal membrane oxygenation for pulmonary embolism.Frontiers in medicine · 2025Pooled it
- Role of ECMO and percutaneous mechanical thrombectomy in the management of acute pulmonary embolism.Frontiers in cardiovascular medicine · 2026Review
- Evolving Management of Acute Pulmonary Embolism with Extracorporeal Membrane Oxygenation-A Narrative Review.Journal of clinical medicine · 2025Review
- Venous thromboembolism following lung transplantation.World journal of transplantation · 2025Review
- Contemporary treatment of right ventricular failure.JHLT open · 2025Review
- Novel Therapies for Right Ventricular Failure.Current cardiology reports · 2025Review
- Survival after venoarterial extracorporeal membrane oxygenation for acute high-risk Pulmonary Embolism: A meta-analysis of comparative studies.Pakistan journal of medical sciences · 2025Review
- Role of Extracorporeal Membrane Oxygenation in the Treatment of Massive Pulmonary Embolism.The International journal of angiology : official publication of the International College of Angiology, Inc · 2024Review
- Management of high-risk pulmonary embolism in the emergency department: A narrative review.The American journal of emergency medicine · 2024Review
- Critical Care Management of Acute Venous Thromboembolism: Integrating Pharmacotherapy, Thrombectomy, and Temporary Mechanical Support.US cardiology · 2024Review
- Current status of ECMO for massive pulmonary embolism.Frontiers in cardiovascular medicine · 2023Review
- Management of High-Risk Pulmonary Embolism: What Is the Place of Extracorporeal Membrane Oxygenation?Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venoarterial extracorporeal membrane oxygenation (ECMO) has been used to treat acute massive pulmonary embolism (PE) patients. However, the incremental benefit of ECMO to standard therapy remains unclear. Our meta-analysis objective is to compare in-hospital mortality in patients treated for acute massive PE with and without ECMO. The National Library of Medicine MEDLINE (USA), Web of Science, and PubMed databases from inception through October 2020 were searched. Screening identified 1002 published articles. Eleven eligible studies were identified, and 791 patients with acute massive PE were included, of whom 270 received ECMO and 521 did not. In-hospital mortality was not significantly different between patients treated with vs. without ECMO (OR = 1.24 [95% CI, 0.63-2.44], p = 0.54). However, these findings were limited by significant study heterogeneity. Additional research will be needed to clarify the role of ECMO in massive PE treatment. In-hospital mortality for patients with acute massive pulmonary embolism was not significantly different (OR of 1.24, p = 0.54) between those treated with and without venoarterial ECMO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.